Malgorzata Misiewicz
Overview
Explore the profile of Malgorzata Misiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Robak P, Drozdz I, Jarych D, Mikulski D, Weglowska E, Siemieniuk-Rys M, et al.
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32916955
Bortezomib is the first-in-class proteasome inhibitor, commonly used in the treatment of multiple myeloma (MM). The mechanisms underlying acquired bortezomib resistance in MM are poorly understood. Several cell-free miRNAs have...
12.
Robak P, Weglowska E, Drozdz I, Mikulski D, Jarych D, Ferlinska M, et al.
Mediators Inflamm
. 2020 Jun;
2020:1835836.
PMID: 32587468
The aim of the study was to determine the levels of selected cytokines and chemokines in the serum of multiple myeloma (MM) patients treated with bortezomib-based regimens. A total of...
13.
Kubczak M, Szustka A, Blonski J, Gucky T, Misiewicz M, Krystof V, et al.
Mol Med Rep
. 2019 Mar;
19(5):3593-3603.
PMID: 30864706
Chronic lymphocytic leukemia (CLL) treatment is improving; however, some patients do not respond to therapy. Due to the high heterogeneity in disease development, there is an urgent need for personalization...
14.
Nowicki M, Szemraj J, Wierzbowska A, Misiewicz M, Malachowski R, Pluta A, et al.
Eur J Haematol
. 2018 Jan;
100(5):426-435.
PMID: 29380440
Objective: MicroRNAs engaged in angiogenesis and hematopoiesis can influence hematopoietic stem cells (HSCs) homing after transplantation by targeting bone marrow niche microenvironment. This study aimed to examine the kinetics of...
15.
Franiak-Pietryga I, Ostrowska K, Maciejewski H, Appelhans D, Misiewicz M, Ziemba B, et al.
Macromol Biosci
. 2016 Dec;
17(5).
PMID: 27996200
Although chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western world, it remains incurable with conventional chemotherapeutic agents. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is an...
16.
Franiak-Pietryga I, Maciejewski H, Ostrowska K, Appelhans D, Voit B, Misiewicz M, et al.
Int J Biol Macromol
. 2016 Mar;
88:156-61.
PMID: 26987432
Chronic lymphocytic leukemia (CLL) is one of the most prevalent forms of leukemia in western society. Although classic chemoimmune therapy is still the gold standard of care for leukemic patients,...
17.
Smolewski P, Robak P, Cebula-Obrzut B, Misiewicz M, Medra A, Majchrzak A, et al.
Eur J Cancer
. 2014 Aug;
50(15):2677-84.
PMID: 25154027
SMIP-016, a new anti-tumour agent, is a mouse/human chimeric fusion protein built on the ADAPTIR™ (modular protein therapeutic) platform targeting human CD37. In this study, for the first time, we...
18.
Misiewicz M, Robak M, Chojnowski K, Trelinski J
Pol Merkur Lekarski
. 2014 Jun;
36(215):316-9.
PMID: 24964508
Unlabelled: Multiple myeloma (MM) is associated with the increased risk of thrombosis. Hypofibrinolysis is among the various identified abnormalities in the hemostasis system that may cause a prothrombotic state. The...
19.
Trelinski J, Misiewicz M, Robak M, Smolewski P, Chojnowski K
Thromb Res
. 2014 Jan;
133(4):667-70.
PMID: 24451990
Introduction: Patients with multiple myeloma (MM) have an increased risk of thromboembolic events (TEE). Due to the complex nature of the prothrombotic state in MM, no single laboratory test has...